Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.

ABSTRACT: Amplified and/or mutated MET can act as both a primary oncogenic driver and as a promoter of tyrosine kinase inhibitor (TKI) resistance in non-small cell lung cancer (NSCLC). However, the landscape of MET-specific targeting agents remains underdeveloped, and understanding of mechanisms of resistance to MET TKIs is limited. Here, we present a case of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET, who after progression on erlotinib responded dramatically to combined MET and EGFR inhibition with savolitinib and osimertinib. When resistance developed to this combination, a new MET kinase domain mutation, D1228V, was detected. Our in vitro findings demonstrate that MET^D1228V induces resistance to type I MET TKIs through impaired drug

SUBMITTER: Bahcall M 

PROVIDER: S-EPMC5140694 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature